The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 19, 2025
Filed:
Aug. 17, 2023
Applicant:
Medimmune Limited, Cambridge, GB;
Inventors:
Andrew Buchanan, Cambridge, GB;
Sven Nylander, Sodertalje, SE;
Mark Penney, Cambridge, GB;
Philip Newton, Cambridge, GB;
Feenagh Keyes, Cambridge, GB;
Tord Inghardt, Sodertalje, SE;
Assignee:
Medimmune Limited, Cambridge, GB;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); C07D 487/04 (2006.01); C07K 16/44 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/44 (2013.01); C07D 487/04 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract
The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.